相关实验视频

Updated: Jan 8, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

BRAF/MEK抑制的心脏毒性作用:一项观察性研究

Jannek Brauer¹, Daniel Scheidet², Sebastian Romann¹

¹University Hospital Heidelberg, Department of Cardiology, Heidelberg, Germany; German Center of Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim, Germany.

European journal of cancer (Oxford, England : 1990)

|December 19, 2025

概括

与癌症治疗有关的心脏功能障碍 (CTRCD) 影响了44%的接受BRAF/MEK抑制剂的患者. 冠状动脉疾病是关键的风险因素,突出了癌症治疗期间需要动态心脏监测的需要.

科学领域:

心脏瘤学是一门专业.
在瘤学瘤学.
心血管医学心血管医学

背景情况:

BRAF/MEK抑制剂对于BRAF突变癌症至关重要.
这些抑制剂的心血管副作用还没有得到很好的定义.
使用现代定义,关于癌症治疗相关心脏功能障碍 (CTRCD) 的数据有限.

研究的目的:

在接受BRAF/MEK抑制剂的患者中确定CTRCD的发病率和危险因素.
使用国际心脏瘤学会 (ICOS) 的标准,包括成像和生物标志物.
使用当代的,全面的定义来评估CTRCD.

主要方法:

对75名接受BRAF/MEK抑制剂治疗的患者进行前性监测.
在基线和随访时进行心声回声 (包括GLS),hs-cTnT和NT-proBNP评估.
根据ICOS标准对CTRCD的分类;根据ESC类别进行基线风险分层.

主要成果:

在44%的患者中发生了CTRCD (轻度17%,中度23%,重度4%).
冠状动脉疾病是唯一重要的基线预测因子 (OR 11.0,p=0.029).
传统的风险因素和基线生物标志物 (hs-cTnT,NT-proBNP,LVEF) 不具有预测性.

结论:

在接受BRAF/MEK抑制剂的患者中,CTRCD很常见.
冠状动脉疾病是CTRCD的重要风险标志物.
动态监测策略对于管理这些患者心脏毒性至关重要.

关键词:

BRAF 抑制剂的使用在CTRCD中,使用的是CTRCD.心脏生物标志物心脏生物标志物心脏瘤学是一门专业.心脏有毒性 - 心脏有毒性全球纵向菌株全球纵向菌株作为MEK抑制剂的使用.

更多相关视频

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

相关概念视频

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...